India's Cipla extends losses on trimming FY26 margin outlook

Cipla

31/10/2025 04:38

** Cipla CIPL.NS drops ~2% to 1,514.30 rupees; had lost 2.6% in last session

** On analyst call, India's no. 3 drugmaker lowers FY26 EBITDA margin outlook, citing declining contribution from generic Revlimid, higher R&D costs

** CLSA sees tepid H2 for co, almost negligible contribution from gRevlimid

** On Thursday, Cipla beat Q2 profit view, announced CEO rejig

** Stock rated "buy" on avg; median PT is 1,720 rupees, per data compiled by LSEG

** YTD, CIPL gains 0.9%

 (Reporting by Kashish Tandon)

 ((Kashish.tandon@thomsonreuters.com; +91 8800437922))